Replies to post #34502 on Humanigen Inc (fka HGENQ)

[cowtown jay]

Thank you, portage. That post was a pain in the butt to write. There were three times when I tried to get all the information I needed, each effort taking about two hours, before I scaled back and just posted what I did.

But to me, Cameron's discussion during the presentation, and during the Q&A session, was profound. It reflected core values that I have written about previously, such as in expressing our need to be, "... ready to start that all-important revenue stream, which I think is basically forcing the FDA's hand to approve us, or answer to HHS and DOD as to why all of our lenz is being sold overseas." That was a sentiment expressed by Durrant, also. As was focusing on the human cost of this neglectfully delayed authorization, whether it was in regards to the one patient I have written about, or the potentially 75K other US patients who have died needlessly without this drug.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166146273&txt2find=168219

I think that Humanigen has become tempered-tough. And while I was disappointed that ALL of our trial data, including CRP, was not accepted yet for Lancet publication, the plus side to writing a manuscript that focuses on that subject alone, will only serve to shine the brightest spotlight on our most significant accomplishment.

I'm very excited about our potential, to include Wainwright's share price projection for sotrovimab, which only serves as an example of what an effective mAb therapeutic is worth to the market.